Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009

David B. Hanna, Kate Buchacz, Kelly A. Gebo, Nancy A. Hessol, Michael A. Horberg, Lisa P. Jacobson, Gregory D. Kirk, Mari M. Kitahata, P. Todd Korthuis, Richard D. Moore, Sonia Napravnik, Pragna Patel, Michael J. Silverberg, Timothy R. Sterling, James H. Willig, Ann C. Collier, Hasina Samji, Jennifer E. Thorne, Keri N. Althoff, Jeffrey N. Martin, Benigno Rodríguez, Elizabeth A. Stuart, Stephen J. GangePLoS 2013 · DOI

TL;DR

This study investigates how state-level differences in AIDS Drug Assistance Programs (ADAPs) impact the timely initiation of HIV antiretroviral therapy (ART). It reveals that states not contributing additional funding to their ADAP budgets are associated with delays in ART initiation, highlighting the crucial role of state financial commitment in ensuring prompt treatment for individuals with HIV.

What Problem Does This Paper Address?

The U.S. National HIV/AIDS Strategy prioritizes reducing health disparities, yet significant variations in HIV care outcomes persist across states. A key factor contributing to these disparities is the structure and funding of State AIDS Drug Assistance Programs (ADAPs). ADAPs act as a safety net, providing ART to individuals who are uninsured or underinsured. However, states administer these programs independently, leading to differences in financial contributions, eligibility criteria, and implementation strategies, such as waiting lists. It's unclear how these state-level variations influence crucial treatment outcomes like the timely initiation of ART, which is critical for managing HIV infection and preventing disease progression. This paper aims to bridge that knowledge gap by examining the association between specific ADAP features and ART initiation and virologic suppression.

Methods

The researchers employed a combination of statistical methods to analyze data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

  • Propensity Score Matching (PSM): This technique was used to create comparable groups of individuals. For each ADAP feature (e.g., state funding, waiting lists), participants living in states with that feature ("exposed") were matched with similar participants living in states without that feature ("unexposed"). This helps to control for potential confounding factors and isolate the effect of the ADAP feature itself.
  • Cox Regression: After matching, Cox proportional hazards regression models were used to assess the time to ART initiation (within six months of eligibility) and the time to virologic suppression (within one year of eligibility). This method is suitable for analyzing time-to-event data.
  • Dose-Response Analysis: For the state contribution to ADAP budgets, a dose-response analysis was conducted to see if increasing levels of state funding were associated with progressively better outcomes.
  • Conventional Cox Regression: This was used as a secondary analysis and for specific subgroup analyses (like individuals with a history of injection drug use) where PSM might not achieve adequate balance.

Datasets

The study utilized data from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), a collaboration of over 100,000 individuals from more than 100 HIV cohorts in the U.S. and Canada. The specific dataset for this analysis comprised 8,874 HIV-infected individuals who were clinically eligible for ART between 2001 and 2009. Eligibility was defined by either a first reported CD4+ count below 350 cells/µL or an AIDS-defining illness.

Key Insights and Ideas

  • State Funding Matters: The most significant finding is that states not contributing additional funds to their ADAP budgets were associated with delayed ART initiation. This suggests that while federal funding is a baseline, state financial commitment plays a vital role in ensuring timely access to life-saving treatment.
  • Waiting Lists are Complex: The initial hypothesis was that waiting lists would delay treatment. However, the study found that after controlling for confounders, living in a state with a waiting list was not significantly associated with delayed ART initiation overall. This might indicate that clinics and ADAP offices implement compensatory strategies to help patients navigate these lists, especially for high-need groups like individuals with a history of injection drug use.
  • IDU Subgroup Differences: Individuals with a history of injection drug use (IDU) showed a more pronounced association with delayed ART initiation in states without additional ADAP funding. This highlights how existing health disparities can be exacerbated by systemic issues in treatment access.
  • Virologic Suppression Less Affected: Interestingly, the ADAP features examined (state funding and waiting lists) were not significantly associated with virologic suppression one year after ART eligibility. This could imply that once treatment is initiated, other factors or the effectiveness of ART itself might lead to similar suppression rates across different ADAP contexts, even with initial delays.

Key Results

  • Delayed ART Initiation: Individuals living in states with no additional state contribution to the ADAP budget had a 27% lower likelihood of initiating ART within six months of eligibility (Hazard Ratio [HR] 0.73, 95% CI 0.60-0.88) compared to those in states with contributions.
  • Dose-Response: A significant dose-response relationship was observed: the more a state contributed to its ADAP budget, the lower the hazard of delayed ART initiation.
  • IDU Impact: For individuals with a history of injection drug use, living in a state without additional ADAP funding was associated with a 33% lower likelihood of timely ART initiation (HR 0.67, 95% CI 0.47-0.95).
  • Waiting Lists: Living in a state with an ADAP waiting list was not significantly associated with delayed ART initiation in the propensity score-matched analysis (HR 1.12, 95% CI 0.87-1.45).
  • Virologic Suppression: Neither state contribution nor waiting lists were significantly associated with virologic suppression.

Limitations and Future Work

The authors acknowledge several limitations:

  • Generalizability: The study population primarily consists of individuals from major academic centers, which may limit generalizability to patients not seen in such settings.
  • Ecological Design: The analysis of state-level ADAP features means the effects observed are "contextual" and may not perfectly reflect the experience of individuals who were not actually enrolled in ADAP.
  • Data Quality: ADAP feature data relied on annual surveys, and unmeasured confounding factors (e.g., specific clinic-level interventions not captured) could influence results.
  • Time Period: The study period ends in 2009, preceding significant shifts in HIV treatment guidelines (earlier ART initiation recommendations) and ADAP funding challenges due to economic crises.

Future work should monitor ongoing changes in healthcare funding and ADAP policies, especially in light of the Affordable Care Act, and explore the impact of ADAP formularies on specific comorbidities relevant to HIV-infected individuals. Further research into clinic-specific mechanisms for ART access would also be valuable.

Summary updated

Abstract

We found that living in states that did not contribute additionally to the ADAP budget was associated with delayed ART initiation when treatment was clinically indicated. Given the changing healthcare environment, continued assessment of the role of ADAPs and their features that facilitate prompt treatment is needed.
BibTeX
@inproceedings{hanna2013association,
  author = {David B. Hanna and Kate Buchacz and Kelly A. Gebo and Nancy A. Hessol and Michael A. Horberg and Lisa P. Jacobson and Gregory D. Kirk and Mari M. Kitahata and P. Todd Korthuis and Richard D. Moore and Sonia Napravnik and Pragna Patel and Michael J. Silverberg and Timothy R. Sterling and James H. Willig and Ann C. Collier and Hasina Samji and Jennifer E. Thorne and Keri N. Althoff and Jeffrey N. Martin and Benigno Rodríguez and Elizabeth A. Stuart and Stephen J. Gange},
  title = {{Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001–2009}},
  booktitle = {PLoS},
  year = {2013},
  doi = {10.1371/journal.pone.0078952},
}
Figure